Cerebras Systems vs. Nebius Group N.V.: Which AI Hardware Stock Is a Better Buy in 2026?

Nebius is presented as the preferred high-risk AI infrastructure investment for 2026, supported by a lower 49.0x forward P/E and 47.6x P/S multiple versus Cerebras at 222x and 71.2x, respectively. Nebius generated approximately $530 million of FY2025 revenue, up 351%, but burned nearly $3.7 billion in free cash flow; Cerebras posted $510 million of revenue, up 76%, alongside $238 million of net income but negative $393 million in free cash flow. Consensus projects Nebius revenue rising to $3.3 billion in 2026 and $23 billion by 2028, versus Cerebras reaching $888 million and $7.5 billion, though the article stresses that both sets of long-term estimates are highly speculative.

Analysis

The relevant distinction is not hardware versus cloud but capital intensity and revenue durability. NBIS must continually fund data-center capacity ahead of utilization, making its equity unusually sensitive to financing costs, GPU availability, and any pause in customer commitments; a modest utilization miss can translate into disproportionate FCF and multiple pressure. CBRS has lower infrastructure ownership exposure but its economics depend on proving that workload-specific performance translates into repeatable deployments rather than a small number of strategic customers or benchmark-driven wins.

Consensus is likely treating multi-year revenue estimates as independent demand forecasts when they are largely a joint function of AI capex, available power, and customer concentration. Hyperscalers can absorb temporary underutilization and bundle compute with existing software ecosystems; smaller providers cannot, so price competition should first surface in NBIS gross margin and contract duration. Conversely, an inference shift toward latency- and power-constrained workloads would be more favorable to CBRS than to GPU-cloud operators, but only if software portability and supply capacity remove adoption friction.

Over the next 1-3 months, verify contracted capacity, customer prepayments, utilization, capex commitments, and whether reported cash generation excludes economically dilutive SBC. Over 6-18 months, the key catalyst is whether AI spending moves from training build-out to production inference: that would support specialized silicon and potentially compress generic GPU-rental pricing. The contrarian view is that both equities remain vulnerable even if AI demand stays strong, because revenue growth alone will not justify valuations unless incremental revenue converts to durable gross profit and positive post-capex cash flow.

Key Decisions for Investors

• Do not chase either name on top-line projections alone; establish a diligence alert before earnings for NBIS contracted backlog, utilization, capex-to-revenue ratio, and net debt. A recommendation to own NBIS requires evidence that incremental capacity is being contracted before deployment rather than financed speculatively.
• Prefer a 3-6 month relative-value position long NVDA / short NBIS if NBIS trades materially higher after AI-capex headlines: NVDA retains ecosystem pricing power and benefits from cloud build-outs, while NBIS bears utilization and financing risk. Cover the short if NBIS discloses multi-year take-or-pay commitments sufficient to cover planned capacity and raises utilization/gross-margin guidance.
• For higher-risk thematic exposure, use a small CBRS position only after its next results confirm customer diversification and positive operating cash conversion; size it as a venture-style allocation, not a core semiconductor holding. Exit on a material reduction in partner demand, manufacturing delays, or a failure of inference revenue to scale faster than R&D and working-capital needs.
• Monitor AMZN, MSFT, and GOOG AI infrastructure capex commentary as the near-term read-through. Any coordinated moderation in 2027 capacity plans is a faster negative catalyst for NBIS and other capacity lessors than for hyperscalers, and would likely trigger sharp multiple compression across both CBRS and NBIS.